Accelerate Diagnostics (AXDX) Scheduled to Post Earnings on Tuesday

Accelerate Diagnostics (NASDAQ:AXDX) will post its quarterly earnings results after the market closes on Tuesday, November 6th. Analysts expect Accelerate Diagnostics to post earnings of ($0.44) per share for the quarter.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings results on Monday, August 6th. The medical research company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). The business had revenue of $1.69 million during the quarter, compared to analyst estimates of $2.17 million. Accelerate Diagnostics had a negative return on equity of 67.75% and a negative net margin of 1,405.87%. On average, analysts expect Accelerate Diagnostics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:AXDX opened at $16.18 on Monday. The firm has a market capitalization of $875.79 million, a price-to-earnings ratio of -13.95 and a beta of 2.49. The company has a debt-to-equity ratio of 1.22, a current ratio of 27.12 and a quick ratio of 25.67. Accelerate Diagnostics has a 52 week low of $14.20 and a 52 week high of $30.35.

Several equities analysts have commented on the stock. BidaskClub upgraded shares of Accelerate Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Zacks Investment Research upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $24.00 price target on shares of Accelerate Diagnostics in a research note on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $24.50.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Featured Article: How to Invest in the Dividend Aristocrat Index

Earnings History for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply